AnalystsJason ButlerJason Butler's Stock Forecasts
AnalystsJason Butler
Sectors:
Analyst Ranking
Top 21%
#997 out of 4791 analysts
Average Return
+4.24%
Win Rate
38%50 out of 133
Risk vs Reward
Poor
Good
Jason Butler's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Rezolute IncRZLT | +613.92% | $0.79 | $5.64 | 2023-11-13 - 2024-11-13 | Buy |
Morphosys AgMOR | +316.70% | $4.55 | $18.96 | 2023-11-20 - 2024-08-02 | Buy |
Rezolute IncRZLT | +238.71% | $1.55 | $5.25 | 2023-09-14 - 2024-09-13 | Buy |
Cormedix IncCRMD | +230.33% | $3.33 | $11.00 | 2023-11-14 - 2024-11-14 | Buy |
Aquestive Therapeutics IncAQST | +212.27% | $1.63 | $5.09 | 2023-09-20 - 2024-09-20 | Buy |
Jason Butler Analyst Color
Get additional color on Jason Butler's coverage of popular stocks
Jason Butler's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Precigen IncPGEN | 8 | Buy | $5.00 | +360.83% | Reiterates | 2 days ago |
Cytokinetics IncCYTK | 13 | Buy | $78.00 | +72.45% | Reiterates | 2 days ago |
Argenx SeARGX | 7 | Buy | $696.00 | +4.57% | Maintains | 2 days ago |
Abivax SaABVX | 1 | Buy | $33.00 | +436.59% | Initiates Coverage On | a month ago |
Vigil Neuroscience IncVIGL | 4 | Buy | $22.00 | +1,135.96% | Reiterates | 2 months ago |
Halozyme Therapeutics IncHALO | 9 | Buy | $73.00 | +35.61% | Maintains | 2 months ago |
Aquestive Therapeutics IncAQST | 7 | Buy | $9.00 | +195.08% | Reiterates | 3 months ago |
Zevra Therapeutics IncZVRA | 1 | Buy | $17.00 | +120.78% | Initiates Coverage On | 4 months ago |
Rezolute IncRZLT | 7 | Buy | $7.00 | +48.31% | Reiterates | 4 months ago |
Gh Research PLCGHRS | 4 | Buy | $39.00 | +376.19% | Reiterates | 4 months ago |
Syros Pharmaceuticals IncSYRS | 3 | Buy | $4.00 | +1,580.67% | Maintains | 5 months ago |
Hookipa Pharma IncHOOK | 3 | Buy | $23.00 | +1,136.56% | Maintains | 6 months ago |
Athira Pharma IncATHA | 5 | Buy | $19.00 | +3,471.43% | Reiterates | 7 months ago |
Prothena Corp Public Ltd CoPRTA | 7 | Buy | $83.00 | +555.09% | Maintains | 8 months ago |
Cormedix IncCRMD | 6 | Buy | $19.00 | +69.34% | Reiterates | 9 months ago |
Acadia Pharmaceuticals IncACAD | 11 | Buy | $39.00 | +130.77% | Maintains | 10 months ago |
Morphosys AgMOR | 3 | Buy | $17.00 | N/A | Reiterates | a year ago |
Karuna Therapeutics IncKRTX | 6 | Buy | $318.00 | N/A | Reiterates | a year ago |
Viridian Therapeutics IncVRDN | 5 | Buy | $38.00 | N/A | Maintains | a year ago |
Gamida Cell LtdGMDAQ | 9 | Buy | $6.00 | N/A | Reiterates | a year ago |
Ironwood Pharmaceuticals IncIRWD | 1 | Buy | $22.00 | N/A | Initiates Coverage On | a year ago |
Trevena IncTRVN | 2 | Buy | $50.00 | N/A | Reiterates | 2 years ago |
Minerva Neurosciences IncNERV | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Plx Pharma IncPLXPQ | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Applied Molecular Transport IncAMTI | 2 | Buy | $50.00 | N/A | Maintains | 3 years ago |
Marinus Pharmaceuticals IncMRNS | 2 | Buy | $22.00 | N/A | Maintains | 3 years ago |
Quince Therapeutics IncQNCX | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Arena Pharmaceuticals IncARNA | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Enanta Pharmaceuticals IncENTA | 4 | Buy | $116.00 | N/A | Maintains | 3 years ago |
Arbutus Biopharma CorpABUS | 1 | Buy | $9.00 | N/A | Maintains | 3 years ago |
Adamas Pharmaceuticals IncADMS | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Esperion Therapeutics IncESPR | 1 | Buy | $111.00 | N/A | Maintains | 4 years ago |
Ovid Therapeutics IncOVID | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Pfenex IncPFNX | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Zogenix IncZGNX | 1 | Buy | $56.00 | N/A | Initiates Coverage On | 7 years ago |
Intra Cellular Therapies IncITCI | 1 | Buy | N/A | N/A | Upgrades | 7 years ago |
Forward Pharma AFWPAY | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.